01/08/2026
Dec 2025: FDA approves EXDENSUR, an ultra-long-acting asthma biologic with just 2 doses per year. Indication: severe eosinophilic asthma. Dosing: every 6 months.
EXDENSUR (depemokimab-ulaa) is now approved. Download Prescribing Information and sign up to learn more about EXDENSUR.